WATCHMAN Checks: Standalone Still Growing While Concomitant Ramps Strongly

Research evidence excerpt

WATCHMAN Checks: Standalone Still Growing While Concomitant Ramps Strongly

USA | Medical Supplies & Devices

Boston Scientific EquityMayResearch12, 2026

COMPANY UPDATEWATCHMAN Checks: Standalone Still Growing

RATING BUYWhile Concomitant Ramps Strongly

PRICE $53.37^

Since the 1Q print, investors have had concerns about the trajectory of

standalone WATCHMAN/LAAC procedures. As a first step, we collated PRICE TARGET | % TO PT $100.00 | +87%

feedback from doctor checks since CHAMPION to understand how standalone 52W HIGH-LOW $109.50 - $53.15

and concomitant procedures could grow in '26 and in the future. The punchline FLOAT (%) | ADV MM (USD) 98.4% | 1,030.36

is physicians still expect standalone procedures to grow and are predicting MARKET CAP $79.8B

dramatic growth in concomitant procedures, which should be supportive of TICKER BSX ^Prior trading day's closing price unless otherwise

BSX's recast guide. noted.

We have conducted several KOL checks since the CHAMPION study read-out that reflect a Cal CHANGE TO JEFe JEF vs CONS

consensus view that the study was an overall success and should lead to increased LAAC 2026 2027 2026 2027

volumes, especially in concomitant procedures. That said, most of these physicians expect the REV NA NA NM NM

traditional standalone indication to continue to grow, particularly for those with high bleeding risk EPS NA NA +1% +2%

and called out patient preference to get off OACs, real world issues with compliance, nuisance

bruising and minor bleeding as other motivations to choose LAAC over a drug regimen.

2026 ($) Q1A Q2 Q3 Q4 Cal

Further, feedback on the concomitant data and potential for growth in that indication has been EPS 0.80 0.84 0.85 0.91 3.41

very positive post CHAMPION with OPTION further supported by strong data in the ablated PREV